The rapid rise of GLP-1 weight-loss medications is creating new considerations for employers as health plan costs and workplace policies evolve. Legal analysts at Fisher Phillips say companies are weighing whether to cover the drugs, which are not federally required benefits but are seeing increased use among employees. Some large employers report higher prescription spending tied to demand for the treatments, highlighting the challenge of balancing benefit affordability with workforce expectations.

“Rising demand does not automatically mean open-ended coverage,” said Dave O’Neil, director of communications for the Ohio Manufacturers’ Association. “Employers have a responsibility to protect sustainability, fairness and affordability for the whole workforce.” 2/23/2026